Instil Bio announced poster presentations of pre-clinical data and trial-in-progress for the ongoing ITIL-306 Phase 1 clinical trial using the CoStimulatory Antigen Receptor, CoSTAR, platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, SITC, to be held from November 8-12, 2022. Pre-clinical data demonstrating the activity of CoStAR across physiologically-relevant ranges of FRalpha expression and TCR affinity are featured in Poster 282. These data demonstrated that CoStAR amplified T-cell responses at all FRalpha expression levels as long as FRalpha was expressed, supporting the clinical exploration of ITIL-306 in multiple solid tumor types with a variety of FRalpha expression levels. Furthermore, CoStAR-expressing cells do not respond to FRalpha in the absence of TCR stimulation, underscoring the expected safety profile of the CoStAR platform. The company also is presenting a trial-in-progress poster summarizing the design of the ongoing Phase 1 study of ITIL-306. ITIL-306-201 is a Phase 1 multicenter, single-arm, dose escalation and expansion study evaluating the safety and feasibility of ITIL-306 in adult patients with advanced epithelial ovarian cancer, non-small cell lung cancer, and renal cell carcinoma who relapsed from or are refractory to greater than or equal to prior line of systemic therapy. Importantly, the Phase 1 study of ITIL-306 features a treatment regimen free of high-dose interleukin-2.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TIL:
